Received radiation therapy to the lung > 30 Gy within 6 months of first dose of study treatment.
Patients who have received radiation within 14 days before the first dose of study treatment
The subject has received therapeutic radiation:\r\n* To the bladder/prostate/rectum pelvis\r\n* To any other site(s) within 28 days of the first dose of study treatment
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
Radiation therapy within 14 days of the first dose of study drug
Patient received radiotherapy within 2 weeks prior to the first dose of study treatment except localized radiation therapy for symptomatic bone metastasis
The subject has received radiation therapy as follows: \r\n* To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has with ongoing complications or is without complete recovery and healing from prior radiation therapy\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
The subject has received radiation therapy:\r\n* To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment that has with ongoing complications or is without complete recovery and healing from prior radiation therapy (CT changes related to radiation treatment which are not clinical significant are allowed)\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
The subject has received radiation therapy:\r\n* To bone metastasis within 14 days before the first dose of study treatment \r\n* To any other site(s) within 28 days before the first dose of study treatment
Patients enrolled to the prior treatment arm of the dose escalation cohort must not have received anti-cancer therapy less than 14 days prior to the first dose of study drug or palliative, focal radiation therapy less than 14 days prior to the first dose of study drug
The subject has received radiation therapy:\r\n* To the thoracic cavity or gastrointestinal tract within 3 months of the first dose of study treatment\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
No prior radiation therapy within the last 4 weeks, except as below \r\n* To the thoracic cavity, abdomen, or pelvis within 12 weeks before the first dose of study treatment, or has ongoing complications, or is without complete recovery to < grade 1 toxicity\r\n* To bone or brain metastasis within 14 days before the first dose of study treatment\r\n* To any other site(s) within 28 days before the first dose of study treatment\r\n* Prior radiation treatment may have included no more than 3000 centigray (cGy) to fields including substantial bone marrow
Radiation therapy:\r\n* To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has ongoing complications or is without complete recovery and healing from prior radiation therapy\r\n* To bone metastases within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
The subject has received radiation therapy:\r\n* To the thoracic cavity or gastrointestinal tract within 3 months before the first dose of study treatment\r\n* To brain metastasis within 14 days before the first dose of study treatment\r\n* To any other site(s), with the exception of bone, within 28 days before the first dose of study treatment
The subject has received radiation therapy:\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
Anticancer treatment (e.g., radiation therapy, chemotherapy) within 21 days of first dose\r\n* An exception is cetuximab treatment, which can be received within 21 days of the first treatment on study.
The subject has received radiation therapy:\r\n* To the thoracic cavity or gastrointestinal tract within 3 months before the first dose of study treatment\r\n* To bone or brain metastasis within 14 days before the first dose of study treatment\r\n* To any other site(s) within 28 days before the first dose of study treatment
The participant has received radiation therapy:\r\n* To the thoracic cavity or gastrointestinal tract within 3 months of the first dose of study treatment\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
Received radiation (including therapeutic radioisotopes such as strontium 89) therapy ? 3 months prior to the first dose of study treatment and have not recovered from side effects of such therapy (? Grade 1) prior to the first dose of study treatment, except for alopecia.
The subject has received radiation therapy:\r\n* To the thoracic cavity or gastrointestinal tract within 3 months of the first dose of study treatment\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment\r\n* To any other site(s) within 28 days of the first dose of study treatment
The subject has received radiation therapy:\r\n* To the thoracic cavity or abdomen within 3 months before the first dose of study treatment, or has ongoing complications, or is without complete recovery and healing from prior radiation therapy\r\n* To bone or brain metastasis within 3 weeks before the first dose of study treatment\r\n* To any other site(s) within 28 days before the first dose of study treatment
The subject has received radiation therapy:\r\n* To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has with ongoing complications or is without complete recovery and healing from prior radiation therapy\r\n* To bone or brain metastasis within 14 days of the first dose of study treatment
Treatment within 28 days prior to Dose 1 with:
The subject has received radiation therapy within 14 days of the first dose of study treatment
Focal radiation therapy within 4 weeks before first dose of study treatment, or full spinal radiotherapy within 3 months before first dose of study treatment.
Radiation therapy within 28 days of the first dose of study drug
